Pulmonary support for people with myotonic dystrophy during COVID-19 pandemic

Le français suit

 

New COVID-19-related guidance has been produced for people living with myotonic dystrophy who already use some respiratory support at home or who need it if they get sick. These devices are very important to keep you breathing well, but extra care needs to be taken to make sure they are kept clean and to limit the spread of the virus, as they can increase the risk of virus-infected particles being released into the air.

Many people with myotonic dystrophy do not use ventilation when they are otherwise healthy, but some do use non-invasive ventilation at home. Others may require respiratory support if they contract COVID-19 because their breathing muscles are weaker than normal.

Specific guidelines for myotonic dystrophy patients and their doctors in case of a COVID-19 infection, created by Myotonic and the CHEST Home-Based Mechanical Ventilation and Neuromuscular Disease NetWork, can be downloaded HERE.

You can share these recommendations with your care providers and with any medical providers you have to see. Let them know you have myotonic dystrophy and that these guidelines were developed by leading pulmonologists and neurologists specifically for myotonic dystrophy patients suspected of being infected with COVID-19.

If you use respiratory support at home but are currently healthy, see additional guidance about how to avoid exposure to the coronavirus HERE.

 

***

 

 

 

 

De nouveaux conseils liés à la COVID-19 sont disponibles pour les personnes vivant avec la dystrophie myotonique qui utilisent déjà une aide respiratoire à domicile ou qui en ont besoin si elles tombent malades. Ces appareils sont très importants pour vous permettre de bien respirer, mais il faut veiller à ce qu’ils restent propres et à limiter la propagation du virus, car ils peuvent augmenter le risque de libération de particules infectées par le virus dans l’air.

De nombreuses personnes atteintes de dystrophie myotonique n’utilisent pas de ventilation lorsqu’elles sont en bonne santé, mais certaines utilisent une ventilation non invasive à domicile. D’autres peuvent avoir besoin d’une assistance respiratoire si elles contractent la COVID-19 parce que leurs muscles respiratoires sont plus faibles que la normale.

Les directives spécifiques pour les patients atteints de dystrophie myotonique et leurs médecins en cas d’infection par COVID-19, crées par Myotonic et traduites par NMD4C, peuvent être téléchargées ICI.

Vous pouvez partager ces recommandations avec vos professionnels de la santé et avec tous les intervenants médicaux que vous devez consulter. Faites-leur savoir que vous êtes atteint de dystrophie myotonique et que ces recommandations ont été élaborées par des pneumologues et des neurologues de renom, spécifiquement pour les patients atteints de dystrophie myotonique soupçonnés d’être infectés par COVID-19.

Si vous utilisez une assistance respiratoire à domicile mais que vous êtes actuellement en bonne santé, consultez les conseils supplémentaires sur la manière d’éviter l’exposition au coronavirus ICI.

 

lungs

Read next...

2024 Dr David Green Award winners from MDC

NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards

We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.

NMD4C logo with text reading 'Canadian neuromuscular clinical trials network', MDC and IMHA logos at bottom.

NMD4C Launch Canadian Neuromuscular Clinical Trial Network

We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.

Event organizers and participants from SMA outcome measures training, March 2024 in Quebec.

Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network

This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted. 

MDC award $900 000 towards clinical and translational research projects in 2024.

MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants

Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.

SMA outcome measures training graphic

SMA Outcome Measures Training for Physiotherapists and Occupational Therapists

To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.

Congratulations to the 2024 early career award winners. Dr Mireille Khacho and Dr Jean-Philippe Leduc Gaudet.

Congratulations to the 2024 NMD4C Early Career Awards Recipients

We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.